SYNAPS Dx Opens High-Tech Laboratory Supporting Research & Commercialization of DISCERN, Highly Accurate, Minimally Invasive Alzheimer’s Disease Diagnostic Test

SYNAPS Dx Opens High-Tech Laboratory Supporting Research & Commercialization of DISCERN, Highly Accurate, Minimally Invasive Alzheimer’s Disease Diagnostic Test

ROCKVILLE, Md.–(BUSINESS WIRE)–SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is pleased to announce the opening of a new, high-tech laboratory in North Bethesda , MD Greencourt Innovation Center (GIC) for the national launch of DISCERN™, a minimally invasive diagnostic test to identify AD in people with dementia. DISCERN assesses the factors directly related to the formation of synaptic connections in the brain that affect memory loss and cognition in people with AD, as well as regulators of amyloid plaque and tau formation – hallmarks of AD at autopsy.

Martin Rosendale, CEO, Maryland Tech Council, said: “In Maryland, incredible innovations in life sciences and biotechnology are taking place and the DISCERN test is one of them. GIC is an advanced lab with the latest technology available and will serve as a great environment for the important work SDx engineers are doing to identify this devastating disease.”

The test demonstrates >95% sensitivity and specificity even in people recently diagnosed with dementia and is likely to reduce the number of people undergoing expensive and often unreliable PET scans and invasive spinal fluid testing. DISCERN combines three biomarkers: Morphometric imaging to measure the ability of fibroblasts to form networks; Protein Kinase C which correlates with synaptic activity; and AD index to measure the phosphorylation of Erk1 and Erk2 in response to bradykinin.

“The test results will be available within weeks to inform the physician’s diagnosis and the most appropriate intervention for the patient, including medication, a clinical route or recommendations regarding diet, physical activity and mental exercise,” said Frank Amato, CEO and President, SDx. “We are excited to locate our research and commercialization activities in GIC, which has been thoughtfully designed for companies like ours that innovate at a high level.”

SDx will continue to build and scale its commercialization activities, providing prescribers, payers and patients with a major breakthrough diagnostic test for the AD community.

About SYNAPS Dx

SYNAPS Dx is a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD). The company offers DISCERN™, the first highly accurate, minimally invasive test to support a doctor’s definitive diagnosis of AD versus other dementias, even in people who have been recently diagnosed with dementia. The SYNAPS Dx lab is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical lab testing. Physicians and patients seeking more information can visit https://discerntest.com/. For more information about the company, visit https://www.synapsdx.com/. Contact person: info@synapsdx.com.

Similar Posts

Leave a Reply

Your email address will not be published.